Marilixibat chloride is an oral small-molecule ileal bile acid transporter (IBAT)
inhibitor developed by Mirum Pharmaceuticals and approved by
the USFDA for cholestatic pruritus in patients with Alagille
syndrome (ALGS). IBAT facilitates reabsorption of bile acids
from the ileum and is a key facilitator of bile acid enterohepatic
recirculation. Similar to surgical interruption of enterohepatic
recirculation, it was shown that inhibition of IBAT with 22
reduced pruritis in patients with ALGS.
